Flex Pharma,Inc. (NASDAQ:FLKS) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition.

On March 7, 2018, Flex Pharma,Inc. (the "Company") issued a press release announcing its financial results for the year ended December 31, 2017. A copy of the press release is attached hereto as Exhibit99.1 and incorporated herein by reference.

The information in this Item 2.02 and Exhibit99.1 hereto is being furnished and shall not be deemed “filed” for the purposes of Section18 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Flex Pharma, Inc. Exhibit
EX-99.1 2 flks201712318-kpr.htm EXHIBIT 99.1 Exhibit Flex Pharma Reports Year End 2017 Financial Results– FLX-787 Exploratory MS Spasticity Results at the end of March —- FLX-787 Phase 2 ALS & CMT Clinical Studies Ongoing —- Cash to Mid 2019 –Conference Call Scheduled Today at 9:00 a.m. ETMarch 7,…
To view the full exhibit click here

About Flex Pharma,Inc. (NASDAQ:FLKS)

Flex Pharma, Inc. is a biotechnology company. The Company develops treatments for nocturnal leg cramps, muscle cramps and spasms associated with severe neuromuscular conditions, and exercise associated muscle cramps (EAMCs). The Company’s product candidates activate certain receptors in primary sensory neurons, which then act through neuronal circuits to reduce the repetitive firing, or hyperexcitability, of alpha-motor neurons in the spinal cord, thereby preventing or reducing the frequency and intensity of muscle cramps and spasms. The Company operates through developing and commercializing products for nocturnal leg cramps, muscle cramps, spasms and spasticity associated with severe neuromuscular conditions, and exercise-associated muscle cramps segment. The Company’s lead drug product candidate is FLX-787, which is in the Phase II clinical trial stage. It is developing a consumer brand and products specifically formulated to treat athletes suffering from EAMCs.